Clinical Trial Update: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating intravenous ganaxolone added to standard of care for refractory status epilepticus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Status Epilepticus

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Refractory Status Epilepticus | Phase 3 | Status: WITHDRAWN